Prednisolone, a glucocorticoid, reduces bronchitis symptoms by suppressing inflammation. It achieves this primarily by binding to intracellular glucocorticoid receptors.
This binding triggers a cascade of events. Specifically, the complex formed translocates to the nucleus, where it influences gene expression. This affects the production of inflammatory mediators, such as cytokines (like TNF-α and IL-1β) and leukotrienes. Decreased production of these mediators directly reduces airway inflammation and bronchoconstriction.
Simultaneously, Prednisolone modulates the activity of immune cells, like neutrophils and eosinophils, that contribute to the inflammatory response in bronchitis. This dampening of immune cell activity further reduces inflammation and improves lung function.
Additionally, Prednisolone impacts the production of mucus, a key factor in bronchitis. By reducing mucus production, it facilitates easier breathing and helps clear airways. The net result is a reduction in cough, wheezing, and shortness of breath.
Important Note: While Prednisolone effectively manages bronchitis symptoms, it doesn’t cure the underlying infection. It’s typically used in conjunction with other treatments, such as antibiotics or bronchodilators, to provide comprehensive management.
Consult your doctor for personalized advice and treatment. Prednisolone has potential side effects, and proper dosage and monitoring are necessary.
